Inhibin subunit gene expression in ovarian cancer

Gynecologic Oncology

Volumn 73, Issue 2, 1999, Pages 273-279

  Fuller, Peter J ^a   Chu, Simon ^a   Jobling, Tom ^b   Mamers, Pamela ^b   Healy, David L ^b   Burger, Henry G ^a  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Activin; Epithelial tumors; Granulosa cell tumors

Indexed keywords

ACTIVIN; FOLLISTATIN; INHIBIN; RNA;

ARTICLE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

EID: 0032909075     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5356     Document Type: Article

References (37)

1. Venn A, Watson L, Lumley J, Giles G, King C, Healy D: Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 346:995-1000, 1995
2. Rossing MA: Ovarian cancer: a risk of infertility treatment? J Br Fertil Soc 1:46-50, 1996
3. Lappohn RE, Burger HG, Bouma J, Bangah M, Krams M, de Bruijn HW: Inhibin as a marker for granulosa cell tumors. N Engl J Med 321:790-793, 1989
4. Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, Grant P, Day AJ, Rome R, Campbell JJ: Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 329:1539-1542, 1993
5. Jobling T, Mamers P, Healy DL, MacLachlan V, Burger HG, Day AJ: A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol Oncol 55:285-289, 1994
6. Cooke I, O'Brien M, Charnock FM, Groome N, Ganesan TS: Inhibin as a marker for ovarian cancer. Br J Cancer 71:1046-1050, 1995
7. Burger HG, Robertson DM, Cahir N, Mamers P, Healy DL, Jobling T, Groome N: Characterization of inhibin immunoreactivity in post-menopausal women with ovarian tumours. Clin. Endocrinol. 44:413-418, 1996
8. Phocas I, Sarandakou A, Sikiotis K, Rizos D, Kalambokis D, Zourlas PA: A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer. Anticancer Res 16:3827-3831, 1996
9. Rey RA, Lhommé C, Marcillac I, Lahlou N, Duvillard P, Josso N, Bidart JM: Antimüllerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum α-inhibin and estradiol. Am. J. Obstet. Gynecol. 174:958-965, 1996
10. Burger HG, Fuller PJ: The inhibin/activin family and ovarian cancer. Trends Endocrinol Metab 7:197-202, 1996
11. Matzuk MM, Finegold MJ, Su J-GJ, Hsueh AJ.W, Bradley A: α-inhibin is a tumor-suppressor gene with gonadal specificity in mice. Nature 360: 313-319, 1992
12. Di Simone N, Crowley WF Jr, Wang QI-FA, Sluss PM, Schneyer AL: Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 137:486-494, 1996
13. Fuller PJ, Verity K, Shen Y, Mamers P, Jobling T, Burger HG: No evidence of a role for mutations or polymorphisms of the follicle-stimulating hormone receptor in ovarian granulosa cell tumors. J Clin Endocrinol Metab 83:274-279, 1998
14. A subunit and activin type II receptor mRNAs are expressed in human brain tumors. Endoc J 42: 307-313, 1995
15. Mason AJ, Niall HD, Seeburg PH: Structure of two human ovarian inhibins. Biochem Biophys Res Commun 135:957-964, 1986
16. Güssow D, Rein R, Ginjaar I, Hochstenbach F, Seeman G, Kottman A, Ploegh HL: The human β2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol 139:3132-3138, 1987
17. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning - A Laboratory Manual, Second ed, Cold Spring Harbor, Cold Spring Harbor Laboratory, 1989
18. Shen Y, Mamers P, Jobling T, Burger HG, Fuller PJ: Absence of the previously reported G protein oncogene (gip2) in ovarian granulosa cell tumors. J Clin Endocrinol Metab 81:4159-4161, 1996
19. Welt CK, Lambert-Messerlian G, Zheng W, Crowley WFJr, Schneyer AL: Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab 82:3720-3727, 1997
20. Tornos C, Silva EG: Pathology of epithelial ovarian cancer. Obstet Gynecol Clin North Am 21:63-77, 1994
21. Richards JS: Hormonal control of gene expression in the ovary. Endocr Rev 15:725-751, 1994
22. Eramaa M, Heikinheimo K, Tuuri T, Hilden K, Ritvos O: Inhibin/activin subunit mRNA expression in human granulosa-luteal cells. Mol Cell Endocrinol 92:R15-20, 1993
23. Magoffin DA, Jakimiuk AJ: Inhibin A, inhibin B and activin A in the follicular fluid of regularly cycling women. Human Reprod 12:1714-1719, 1997
24. Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, McNeilly AS: Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 81:1401-1405, 1996
25. Roberts VJ, Barth S, El-Roeiy A, Yen SSC: Expression of inhibin/activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle. J Clin Endocrinol Metab 77:1402-1410, 1993
26. Petraglia F, Luisi S, Pautier P, Sabourin J-C, Rey R, Lhomme C, Bidart J-M: Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors. J Clin Endocrinol Metab 83:1029-1032, 1998
27. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A: Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 91:8817-8821, 1994
28. Kumar TR, Wang Y, Matzuk MM: Gonadotropins are essential modifier factors for gonadal tumor development in inhibin-deficient mice. Endocrinology 137:4210-4216, 1996
29. Coerver KA, Woodruff TK, Finegold MJ, Mather J, Bradley A, Matzuk MM: Activin signalling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. Mol Endocrinol 10:534-543, 1996
30. Watson RH, Roy WJ, Davis M, Hitchcock A, Campbell IG: Loss of heterozygosity at the α-inhibin locus on chromosome 2q is not a feature of human granulosa cell tumors. Gynecol Oncol 65:387-390, 1997
31. Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, Robker RL, Richards J-AS, McGinnis LK, Biggers JD, Eppig JJ, Bronson RT, Elledge SJ Weinberg RA: Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384:470-474, 1996
32. Kotlar TJ, Young RH, Albanese C, Crowley WF Jr, Scully RE Jameson JL: A mutation in the follicle-stimulating hormone receptor occurs frequently in human ovarian sex cord tumors. J Clin Endocrinol Metab 82:1020-1026, 1997
33. Kotlar TJ, Young RH, Albanese C, Crowley WF Jr, Scully RE Jameson JL: Absence of mutations in the FSH receptor in ovarian granulosa cell tumors. J Clin Endocrinol Metab 83:3001, 1998
34. Lyons J, Landis CA, Harsh G, et al.: Two G protein oncogenes in human endocrine tumors. Science 249:655-659, 1990
35. Fragoso MCBV, Latronico AC, Carvalho FM, Zerbini MCN, Marcondes JAM, Araujo MB, Lando VS, Frazzatto ET, Mendonca BB, Villares SMF: Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors. J Clin Endocrinol Metab 83:2074-2078, 1998
36. Gurusinghe CJ, Healy DL, Jobling T, Mamers P, Burger HG: Inhibin and activin are demonstrable by immunohistochemistry in ovarian tumor tissue. Gynecol Oncol 57:27-32, 1995
37. Flemming P, Grothe W, Maschek H, Petry KU, Wellmann A, Georgii A: The site of inhibin production in ovarian neoplasms. Histopathology 29:465-468, 1996